INTRODUCTION
Despite advances in chemotherapy and hematopoetic stem cell transplantation, MM is still an incurable malignancy. With highdosed alkylating drugs followed by an autologous stem cell transplantation, a complete remission can be achieved in 40% of the patients (Bjorkstrand et al, 1995 , Attal et al, 2003 . Allogenic stem cell transplantation however is the only curative therapy, but is hampered by elevated treatment related mortality (Crawley et al, 2005) . The cure of certain patients with allogenic transplantation can be explained in part by the killing of MM cells (MMC) by allogenic donor's T cells. This is evidenced by the profound anti-tumor effect of infusions of donor T lymphocytes in patients relapsing after allogenic stem cell transplantation (Tricot et al. 1996) .
One of the targets for a MM-specific immunotherapy is the activation of idiotype-specific Tcells by vaccination with monoclonal immunoglobulin or autologous DC loaded with the monoclonal immunoglobulin (Bergenbrant et al, 1996 , Osterborg et al, 1998 , Massaia et al, 1999 , Reichardt et al, 1999 , Titzer et al, 2000 , Rasmussen et al, 2003 , Coscia et al, 2004 .
Other antigens for T-cell immunotherapy of MM are MAGE-antigens, Sperm-17 and the MUC1 core protein (Treon et al, 2000 , van Baren et al, 1999 , Pellat-Deceunynck et al, 2000b , Lim et al, 2001 , Chiriva-internati et al, 2002 , Choi et al. 2005 . Goto et al. described HM1.24 as a type II transmembrane-glycoprotein with a molecular weight of 29 -33 kD, expressed on terminal differentiated human B-cells (Goto et al, 1994) .
This antibody detects human myeloma cell lines, primary myeloma cells and normal plasma cells. The cloning of the HM1.24-gene showed a homology to the previously described bone marrow stromal protein BST2 gene (Ohtomo et al, 1999) . Some data indicate that BST2 plays a role in the early development of B cells (Ishikawa et al, 1995) . No HM1.24+ cells are found in the peripheral blood, liver, spleen, kidney, or heart of normal individuals (Goto et al, 1994) . HM1.24 is strongly expressed by normal plasma cells or MMC.
Ozaki et al. demonstrated the anti-myeloma activity of anti HM1.24 antibodies in a BALB/c mouse model (Ozaki et al, 1997) . The lysis of MMC by HM1.24 antibodies depends on HM1.24 density on the cell surface (Ohtomo et al, 1999) .
So far HM1.24 immunogenic epitopes that can be recognized by T cells remain to be determined. The aim of this study was the identification of HLA-A2 restricted T cell epitopes within the HM1.24 antigen for future clinical applications like vaccination or the adoptive transfer of T-cells against multiple myeloma.
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MATERIALS AND METHODS
Cell-lines
The myeloma cell lines RPMI-8226 and U266, the EBV transformed plasma-cell line IM-9 and the breast adenocarcinoma cell line MCF-7 were obtained from the German Collection of Microorganisms and Cell Cultures [Braunschweig, Germany] . The hybrid T2 cell line which is deficient in transporter for antigenic peptides (TAP) protein was obtained from American Type Culture Collection [Manassas, VA, USA]. The XG-1 was from Pr B. Klein laboratory (Zhang et al, 1994) . Cell lines were maintained in RPMI 1640 and 10% heat inactivated fetal calf serum (FCS), with IL-6 (10 ng/ml, R&D systems, Abingdon, Oxon, United Kingdom) for the XG-1 cell line.
Prediction and synthesis of immunogenic peptides within the HM1.24 antigen
HM1.24 sequence was scanned for HLA-A2 binding peptides using the prediction software (Parker et al. 1994) . The 8 nona-peptides that had the highest scores both by "Syfpeithi" and "Bimas" were selected for further evaluation.
The predicted peptides were synthesised using standard procedures by the peptidesynthesis-department of the German Cancer Research Center Heidelberg [DKFZ, Heidelberg, Germany] . 
Peripheral blood mononuclear cells (PBMC) for the in vitro expansion of peptide specific Tcells
In vitro obtaining of DC
PBMCs from HLA-A2 + ND were used. Immature DC were obtained culturing plastic adherent
PBMCs for 5 days with GM-CSF (800 U/ml, Molgramostim, Essex Pharma, München, Germany) and IL-4 (500 U/ml, R&D) and then induced into mature DC for 2 days with TNF-α (10 ng/ml, Sigma-Aldrich, Deisenhofen, Germany), IL-6 (1000 U/ml, R&D systems, Abingdon, Oxon, United Kingdom) and prostaglandin E2 (1 µg/ml, Sigma-Aldrich, Deisenhofen, Germany) (Tarte et al. 2000) .
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Expansion of CD40-Ligand activated B-cells
Peripheral blood B-cells were activated and expanded with irradiated (90 Gy) CD40-ligand transfected fibroblasts (Schultze et al, 1997) . After 7 day, activated B cells were used for T cell restimulation. They were pulsed with the HM1.24 peptides (10 µg/ml) and irradiated (30 Gy) and incubated with T cells at a ratio of 1 / 5.
In vitro Expansion of Peptide-specific T-cells with autologous DC and CD40-Ligand activated B-cells
DC were pulsed with HM1.24 peptides (10 µg/ml) for 2 h in serum free RPMI1640 medium and 5 x 10 5 peptide-loaded DC were incubated with 2,5 x 10 6 autologous PBMC in RPMI1640 and 5 % human AB-serum for 7 days . T cells were restimulated with autologous peptide-loaded CD40-ligand activated B-cells with IL-2 (50 U/ml). T-cell restimulations were repeated 3 times and the function of T cells was studied. Cr. Target cells were seeded out in a 96 well round bottom plate and effector cells were added. After an incubation period of 4 h (37° C, 5% CO 2 ) 75 µl supernatant were harvested. The activity was measured using a β HAL author manuscript inserm-00131759, version 1
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plate-counter [Perkin Elmer, Boston USA]. The spontaneous and maximal release was determined in the presence of either medium or 2% Triton X-100, respectively. The specific lysis was calculated as follows: ((test -spontaneous release) / (maximal releasespontaneous release)) x 100 = specific lysis %. Effector:target ratio ranging from 1.25:1 up to 7.5:1 were used. All experiments were assed in triplets. HAL author manuscript inserm-00131759, version 1
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RESULTS
Expression of HM1.24 on plasma cells, myeloma cell lines and primary myeloma cells
In figure 1 Table 1 shows the 8 HM1.24 peptides with the highest propability of binding (predicted by "BIMAS" and "Syfpeithi") and their respective score. While the exact ranking of peptides was different in the two binding prediction softwares, these 8 peptides with the maximum propability of binding were predicted by both the "Syfpeithi" and the "BIMAS" software independently. The HM1.24 peptides listed in table 1 were synthesised and used for the subsequent T cell assays. 
Prediction of immunogenic Peptides within the HM1.24 Antigen
Immunogenic potential of HM 1.24-peptides
Cytotoxicity of HM1.24 aa22-30 specific CD8 + T-cells against HM1.24 aa22-30 peptide loaded T2 cells
In figure 5 the result of the 51 Chromium release-assays is shown. 2 x 10 4 target cells / well were incubated with HM1.24 aa22-30 specific CD8 + T-cells ranging from 1.5 x 10 5 T-cells / well down to 3.75 x 10 4 T-cells / well (effector:target ratio from 1.9:1 to 7.5:1). HM1.24 aa22-30 specific CD8 + T-cells were able to lyse specifically peptide pulsed T2 cells corresponding to the results of the IFN-γ specific ELISpot-assays shown above, with a maximum specific lysis of 25.5% at an effector:target-ratio of 7.5:1.
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DISCUSSION
Several antigens for a specific immunotherapy against multiple myeloma have been described. The myelomal immunoglobulin might be an interesting tumor antigen. T cell epitopes within the variable region of the immunoglobulin were found by several groups (Fagerberg et al, 1999; Hansson et al, 2003; Trojan et al, 2000; Wen et al, 1998) . However, several vaccination trials with the tumor Ig failed to demonstrate any benefit in patients with MM whereas anti-tumor Ig vaccination is a promising strategy in patients with B cell
lymphoma. An explanation could be a deletion of the anti-tumor Ig T cell clones in patients with MM due to the high levels of circulating tumor Ig lasting for several years in the premalignat stage of the disease. Other antigens like MAGE, Sperm-17 or the MUC1 core protein are expressed on only a part of myeloma cells from a subset of patients (Lim et al, 2001; Paydas et al, 2001; Pellat-Deceunynck et al, 2000a; van Baren et al, 1999) . In contrast HM1.24 is found on > 90 % of primary myeloma cells (Goto et al, 1994) . Therefore the identification of T cell epitopes within the HM1.24 antigen may provide a new immunotherapy against multiple myeloma.
Unsing peptide predictor algorithm, IFN-γ ELISpot and cytotoxicity assay, we identified an HM1.24 peptide -aa22-30 -that is efficiently processed and presented by HLA-A2+ and HM1.24+ MMC. Of major interest, DC loaded with HM1.24 aa22-30 can efficiently activate and amplify HM1.24 aa22-30 specific CD8 + cells in vitro.
We were able to expand HM1.24 aa22-30 specific CD8 + cells from 8 out of 11 donors (73 %).
Up to now there are few reports published focussing on the T cell response against HM1.24. HM1.24-aa126-134 peptide (sequence KLQDASAEV) was predicted by the BIMAS software with the highest probability of binding to HLA-A2 molecules. Our data showed that HM1.24
aa126-134 peptide specific T-cells were generated in 6 out of 33 experiments (18 %).
Interestingly a further search with the syfpeithi program showed that Friede described HM1.24 aa125-139 as a HLA-DQA1*0301 / DQB1*0301 restricted T cell epitope (sequence HKLQDASAEVERLRR) (Friede, 2003) . A possible explanation for the low frequency of HLA-HAL author manuscript inserm-00131759, version 1 HM1.24 T CELL EPITOPE A2 restricted HM1.24 aa126-134 peptide specific CD8 + T cell stimulations might be that for the stimulation of CD8 + T-cells the assistance of CD4 + T-cells is necessary. The simultaneous stimulation of CD8 and CD4 T-cells by overlapping epitopes was described by several authors (Carreno et al, 1992; van Binnendijk et al, 1993) . Since HLA-DQA1*0301 / DQB1*0301 is a relatively rare HLA-type with a frequency below 30 % the low frequency of CD8 + T cell stimulations could be correlated to the low coincidence of HLA-A2 + / HLA-DQA1*0301 + / DQB1*0301 + donors. Our first results with HLA-A2 + / HLA-DQA1*0301 + / DQB1*0301 + donors show a successful CD8 + and CD4 + T cell stimulation using the overlapping peptide HM1.24 aa125-139 in two out of two experiments. Further analyses concentrating on this aspect need to be done.
In conclusion, the current data demonstrate that HM1.24 aa22-30 is a good peptide candidate for vaccination of patients with MM with DC or the expansion of anti-MMC T cells in vitro.
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TABLES
